Additionally, current phase III clinical trials are investigating the utility of adding pembrolizumab or dostarlimab (PD-1 blockade) to standard of care chemotherapy in patients with MMR deficient advanced endometrial cancer (NCT03914612 and NCT03981796). This evidence concerns the gene MRC1 and endometrial cancer.